LENSAR reports incentive grants under Nasdaq Rule 5635(c)(4) to Investing.com

ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (LENSAR or the Company) today announced that a majority of the independent members of LENSAR’s board of directors have approved three newly-hired non-executive stock options to purchase a total of 1,650 shares of the Company. The options have been granted since January 2, 2025 as incentive material for every employee employed by the company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $8.69 per share, which is equal to the closing price of the Company’s common stock on the grant date. The options vest at 25% of the total award amount for one year from the date of grant and in thirty-six substantially equal monthly installments thereafter, subject to the new employee’s continued employment with the Company. Each stock option has a term of 10 years. The options are subject to the terms and conditions of LENSAR’s 2024 Employment Incentive Incentive Plan and stock option agreement covering the grant.

About LENSAR

LENSAR is a commercial medical device company focused on the design, development and marketing of advanced systems for treating cataracts and managing astigmatism as an integral aspect of the procedure. LENSAR developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system that uses an ultra-fast dual-modality laser and integrates AI into its own imaging and software. ALLY is designed to transform high-end cataract surgery using LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or outpatient surgical suite, providing operational efficiency and reducing overhead costs. ALLY incorporates LENSAR’s proprietary Streamline® software technology, which is designed to guide surgeons in achieving better results.

Source: LENSAR, Inc.